BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 24969518)

  • 1. Interference of Ca²⁺ with the proliferation of SCCOHT-1 and ovarian adenocarcinoma cells.
    Otte A; Rauprich F; von der Ohe J; Hillemanns P; Hass R
    Int J Oncol; 2014 Sep; 45(3):1151-8. PubMed ID: 24969518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. c-Met inhibitors attenuate tumor growth of small cell hypercalcemic ovarian carcinoma (SCCOHT) populations.
    Otte A; Rauprich F; von der Ohe J; Yang Y; Kommoss F; Feuerhake F; Hillemanns P; Hass R
    Oncotarget; 2015 Oct; 6(31):31640-58. PubMed ID: 26436697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A tumor-derived population (SCCOHT-1) as cellular model for a small cell ovarian carcinoma of the hypercalcemic type.
    Otte A; Göhring G; Steinemann D; Schlegelberger B; Groos S; Länger F; Kreipe HH; Schambach A; Neumann T; Hillemanns P; Park-Simon TW; Hass R
    Int J Oncol; 2012 Aug; 41(2):765-75. PubMed ID: 22581215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner.
    Krysan K; Reckamp KL; Dalwadi H; Sharma S; Rozengurt E; Dohadwala M; Dubinett SM
    Cancer Res; 2005 Jul; 65(14):6275-81. PubMed ID: 16024629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human mesenchymal stroma/stem cells exchange membrane proteins and alter functionality during interaction with different tumor cell lines.
    Yang Y; Otte A; Hass R
    Stem Cells Dev; 2015 May; 24(10):1205-22. PubMed ID: 25525832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells.
    Treeck O; Wackwitz B; Haus U; Ortmann O
    Gynecol Oncol; 2006 Aug; 102(2):292-9. PubMed ID: 16443261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo therapeutic approach for a small cell carcinoma of the ovary hypercalcaemic type using a SCCOHT-1 cellular model.
    Otte A; Rauprich F; Hillemanns P; Park-Simon TW; von der Ohe J; Hass R
    Orphanet J Rare Dis; 2014 Aug; 9():126. PubMed ID: 25103190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.
    Spinella F; Rosanò L; Di Castro V; Nicotra MR; Natali PG; Bagnato A
    Clin Cancer Res; 2004 Jul; 10(14):4670-9. PubMed ID: 15269139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (E)-2,4-Bis(p-hydroxyphenyl)-2-butenal enhanced TRAIL-induced apoptosis in ovarian cancer cells through downregulation of NF-κB/STAT3 pathway.
    Cho SH; Park MH; Lee HP; Back MK; Sung HC; Chang HW; Kim JH; Jeong HS; Han SB; Hong JT
    Arch Pharm Res; 2014 May; 37(5):652-61. PubMed ID: 24390815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell cycle arrest or survival signaling through αv integrins, activation of PKC and ERK1/2 lead to anoikis resistance of ovarian cancer spheroids.
    Carduner L; Picot CR; Leroy-Dudal J; Blay L; Kellouche S; Carreiras F
    Exp Cell Res; 2014 Jan; 320(2):329-42. PubMed ID: 24291221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type.
    Lin DI; Chudnovsky Y; Duggan B; Zajchowski D; Greenbowe J; Ross JS; Gay LM; Ali SM; Elvin JA
    Gynecol Oncol; 2017 Dec; 147(3):626-633. PubMed ID: 29102090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of mifepristone on the proliferation, apoptosis, and cis-platinum (DDP) sensitivity of chemo-resistant human ovarian cancer cells].
    Wang G; Zheng WT; Xiao P; Li XJ; Lin TC; Li GY
    Ai Zheng; 2004 Apr; 23(4):406-11. PubMed ID: 15087028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Density-dependent induction of apoptosis by transforming growth factor-beta 1 in a human ovarian carcinoma cell line.
    Mathieu C; Jozan S; Mazars P; Côme MG; Moisand A; Valette A
    Exp Cell Res; 1995 Jan; 216(1):13-20. PubMed ID: 7813613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p38 Mitogen-activated protein kinases is required for counteraction of 2-methoxyestradiol to estradiol-stimulated cell proliferation and induction of apoptosis in ovarian carcinoma cells via phosphorylation Bcl-2.
    Bu SZ; Huang Q; Jiang YM; Min HB; Hou Y; Guo ZY; Wei JF; Wang JW; Ni X; Zheng SS
    Apoptosis; 2006 Mar; 11(3):413-25. PubMed ID: 16538384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
    Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein kinase G type Ialpha activity in human ovarian cancer cells significantly contributes to enhanced Src activation and DNA synthesis/cell proliferation.
    Leung EL; Wong JC; Johlfs MG; Tsang BK; Fiscus RR
    Mol Cancer Res; 2010 Apr; 8(4):578-91. PubMed ID: 20371672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer.
    Macleod K; Mullen P; Sewell J; Rabiasz G; Lawrie S; Miller E; Smyth JF; Langdon SP
    Cancer Res; 2005 Aug; 65(15):6789-800. PubMed ID: 16061661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of progranulin (Acrogranin/PCDGF/Granulin-Epithelin Precursor) in benign and malignant ovarian tumors and activation of MAPK signaling in ovarian cancer cell line.
    Cuevas-Antonio R; Cancino C; Arechavaleta-Velasco F; Andrade A; Barron L; Estrada I; Fernandez RL; Olguin V; Ruiz S; Imani F; Zeferino-Toquero M; Ulloa-Aguirre A; Gerton GL; Diaz-Cueto L
    Cancer Invest; 2010 Jun; 28(5):452-8. PubMed ID: 19863344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma.
    Aguirre D; Boya P; Bellet D; Faivre S; Troalen F; Benard J; Saulnier P; Hopkins-Donaldson S; Zangemeister-Wittke U; Kroemer G; Raymond E
    Apoptosis; 2004 Nov; 9(6):797-805. PubMed ID: 15505422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of pharmacological concentrations of estrogens on growth of 3AO human ovarian cancer cells.
    Li ZB; Chen YX; Zhao JY; Lu J
    Yi Chuan Xue Bao; 2006 Sep; 33(9):782-92. PubMed ID: 16980124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.